Provided by Tiger Trade Technology Pte. Ltd.

REMEGEN

119.900
+1.9001.61%
Volume:3.76M
Turnover:446.15M
Market Cap:67.58B
PE:81.00
High:120.300
Open:118.800
Low:114.600
Close:118.000
52wk High:126.600
52wk Low:32.600
Shares:563.61M
HK Float Shares:208.58M
Volume Ratio:0.76
T/O Rate:1.80%
Dividend:- -
Dividend Rate:- -
EPS(LYR):1.480
ROE:25.37%
ROA:1.37%
PB:16.32
PE(LYR):81.00
PS:18.11

Loading ...

RemeGen Schedules 28 April 2026 Board Meeting to Review Q1 2026 Unaudited Results

Bulletin Express
·
Yesterday

CATL Reports 48.52% Surge in Q1 Net Profit to RMB 20.74 Billion

Stock News
·
Yesterday

National Data Administration Proposes Token Trading Exploration; Central Bank Adjusts Overseas Loan Ratios

Stock News
·
Yesterday

Remegen Receives $650 Million Upfront Payment from AbbVie for RC148 Exclusive Licensing Agreement

Stock News
·
Apr 15

Stock Track | REMEGEN Soars 5.17% Intraday on New Drug Approval and Strong Earnings Turnaround

Stock Track
·
Apr 15

BUZZ-RemeGen set for best day in two weeks on China nod for tumour drug application

Reuters
·
Apr 13

RemeGen Drug Approved For Cancer Indication

MT Newswires Live
·
Apr 13

Stock Track | REMEGEN Soars 5.09% Intraday on New Drug Approval and Strong Revenue Growth

Stock Track
·
Apr 13

Hong Kong Grants First Stablecoin Issuer Licenses as Iran-US Talks Show Major Rifts

Stock News
·
Apr 13

RemeGen receives NMPA approval for Disitamab Vedotin + Toripalimab in HER2-expressing urothelial carcinoma, securing fifth on-label use

Bulletin Express
·
Apr 10

RemeGen Maintains 564.48 Million Share Capital; Confirms Public Float Compliance for March 2026

Bulletin Express
·
Apr 09

RemeGen (HKG:9995) Is Posting Healthy Earnings, But It Is Not All Good News

Simply Wall St.
·
Apr 04

China International Capital Corp. Highlights Positive Trends in Domestic Innovative Drug Sector, Anticipates Key Academic Developments in 2026

Stock News
·
Apr 03

China International Capital Corporation Maintains Outperform Rating on REMEGEN, Raises Target Price to HK$133.7

Stock News
·
Apr 03

Lilly's Oral GLP-1 Weight Loss Drug Receives FDA Approval, Offering Daily Pill Alternative to Injections

Deep News
·
Apr 03

RemeGen (SEHK:9995) Is Up 30.0% After New HER2-Low Breast Cancer Approval Has The Bull Case Changed?

Simply Wall St.
·
Apr 03

RemeGen Receives Chinese Regulatory Nod for RC288 Clinical Trial

MT Newswires Live
·
Apr 02

Stock Track | RemeGen Soars 5.07% Intraday Following NMPA Approval for Phase I/IIa Trial of Bispecific ADC RC288

Stock Track
·
Apr 02

RemeGen secures NMPA green light for Phase I/IIa trial of bispecific ADC RC288 targeting PSMA/B7H3

Bulletin Express
·
Apr 01

Remegen Receives Clinical Trial Approval for Bispecific ADC Drug RC288

Stock News
·
Apr 01